- Home
- PGHL vs YMAB Comparison
PGHL vs YMAB Comparison
Compare PGHL & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGHL
- YMAB
- Stock Information
- Founded
- PGHL 2018
- YMAB 2015
- Country
- PGHL Hong Kong
- YMAB United States
- Employees
- PGHL N/A
- YMAB N/A
- Industry
- PGHL
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PGHL
- YMAB Health Care
- Exchange
- PGHL NYSE
- YMAB Nasdaq
- Market Cap
- PGHL N/A
- YMAB 270.5M
- IPO Year
- PGHL 2024
- YMAB 2018
- Fundamental
- Price
- PGHL $0.50
- YMAB $4.50
- Analyst Decision
- PGHL
- YMAB Buy
- Analyst Count
- PGHL 0
- YMAB 11
- Target Price
- PGHL N/A
- YMAB $18.73
- AVG Volume (30 Days)
- PGHL 175.7K
- YMAB 322.9K
- Earning Date
- PGHL 05-21-2025
- YMAB 03-04-2025
- Dividend Yield
- PGHL N/A
- YMAB N/A
- EPS Growth
- PGHL N/A
- YMAB N/A
- EPS
- PGHL N/A
- YMAB N/A
- Revenue
- PGHL $17,166,534.00
- YMAB $87,685,000.00
- Revenue This Year
- PGHL N/A
- YMAB $20.07
- Revenue Next Year
- PGHL N/A
- YMAB $8.76
- P/E Ratio
- PGHL $14.78
- YMAB N/A
- Revenue Growth
- PGHL 56.11
- YMAB 3.38
- 52 Week Low
- PGHL $0.45
- YMAB $4.25
- 52 Week High
- PGHL $107.36
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- PGHL N/A
- YMAB 36.51
- Support Level
- PGHL N/A
- YMAB $4.65
- Resistance Level
- PGHL N/A
- YMAB $5.25
- Average True Range (ATR)
- PGHL 0.00
- YMAB 0.30
- MACD
- PGHL 0.00
- YMAB 0.02
- Stochastic Oscillator
- PGHL 0.00
- YMAB 21.92
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.